SCHEMBL3391084

SCHEMBL3391084

CC1C(C)(C)C1(C)C(N)=O

nearest known ligand 0.35

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.35
LMNA P02545 1/20 0.32
ALOX15 P16050 1/20 0.32
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31294823 0.74
SCHEMBL1376057 0.73 MAPK1 (0.44) LMNABLMPMP22
SCHEMBL4632184 0.72 CRBN (0.39)
SCHEMBL3392541 0.71
Hydrochloric Acid SCHEMBL11238901 0.71 MAPK1 (0.42) LMNABLMPMP22
SCHEMBL10017926 0.67
SCHEMBL4202941 0.67
SCHEMBL15541624 0.65 PKM (0.31) PKM
SCHEMBL15540948 0.65 PKM (0.31) PKM
SCHEMBL19920645 0.64 PKM (0.39) PKMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102442970-A Thiazole compounds as cannabinoid receptor ligands and uses thereof ABBOTT LAB 2012-05-09 CN claimed
WO-2005030734-A1 DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS ABBOTT LABORATORIES (US) 2005-04-07 WO claimed
EP-2737901-B1 Therapeutic Use of Compounds UCL BUSINESS LTD (GB) 2021-03-03 EP disclosed
EP-3636259-A1 THERAPEUTIC USE OF COMPOUNDS UCL BUSINESS LTD (GB) 2020-04-15 EP disclosed
EP-2642990-B1 THERAPEUTIC USE OF COMPOUNDS UCL BUSINESS PLC (GB) 2019-09-18 EP disclosed
US-9023844-B2 Heterocyclylpyri (mi) dinylpyrazole as fungicidals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-05-05 US disclosed
US-20140256677-A1 HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-11 US disclosed
EP-2737901-A1 Therapeutic Use of Compounds UCL Business PLC (GB) 2014-06-04 EP disclosed
EP-2222165-B1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBVIE INC (US) 2013-07-31 EP disclosed
US-20120264827-A1 SULFANYLAMIDE DERIVATIVES, USES THEREOF AND COMPOSITIONS COMPRISING THEM YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2012-10-18 US disclosed
EP-2480527-A1 SULFANYLAMIDE DERIVATIVES, USES THEREOF AND COMPOSITIONS COMPRISING THEM Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) 2012-08-01 EP disclosed
US-20060148861-A1 Amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid YISSUM RESEARCH DEVELOPEMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-07-06 US disclosed
EP-1603891-A1 NEW AMIDE DERIVATIVES OF 2,2,3,3-TETRAMETHYLCYCLOPROPANE CARBOXYLIC ACID YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2005-12-14 EP disclosed
US-6960687-B2 Derivatives and pharmaceutical compositions of n-hydroxyalkyl tetramethylcyclopropane-carboxamide, having anti-epiletic, neurological, and CNS activity, and method for their preparation YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2005-11-01 US disclosed
US-20050131069-A1 Derivatives and pharmaceutical compositions of n-hydroxyalkyl tetramethylcyclopropane-carboxamide, having anti-epiletic, neurological, and cns activity, and method for their preparation YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) 2005-06-16 US disclosed
EP-1487787-A1 DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF N-HYDROXYALKYL TETRAMETHYLCYCLOPROPANE-CARBOXAMIDE, HAVING ANTI-EPILEPTIC, NEUROLOGICAL, AND CNS ACTIVITY, AND METHOD FOR THEIR PREPARATION Yissum Research Development Company of the Hebrew University of Jerusalem (IL) 2004-12-22 EP disclosed
WO-2004076432-A1 NEW AMIDE DERIVATIVES OF 2,2,3,3-TETRAMETHYLCYCLOPROPANE CARBOXYLIC ACID YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-09-10 WO disclosed
WO-2003064374-A1 DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF N-HYDROXYALKYL TETRAMETHYLCYCLOPROPANE-CARBOXAMIDE, HAVING ANTI-EPILEPTIC, NEUROLOGICAL, AND CNS ACTIVITY, AND METHOD FOR THEIR PREPARATION YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2003-08-07 WO disclosed
US-5880157-A ANTIEPILEPTIC AGENTS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1999-03-09 US disclosed
WO-1995021814-A1 NOVEL DERIVATIVES OF TETRAMETHYLCYCLOPROPANE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 1995-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256677-A1 HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS CCNY, NQO2, H1-0 PKM 2090/4885LMNA 958/4885ALOX15 3985/4885
US-20050131069-A1 Derivatives and pharmaceutical compositions of n-hydroxyalkyl tetramethylcyclopropane-carboxamide, having anti-epiletic, neurological, and cns activity, and method for their preparation SCN1A, MAG, SCN8A PKM 1097/4885LMNA 482/4885ALOX15 1077/4885
US-20060148861-A1 Amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid CNR2, GRIN2A, GRIN2C PKM 1134/4885LMNA 2874/4885ALOX15 1256/4885
US-20120264827-A1 SULFANYLAMIDE DERIVATIVES, USES THEREOF AND COMPOSITIONS COMPRISING THEM CNR2, SULT2A1, CYP2S1 PKM 3838/4885LMNA 2408/4885ALOX15 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.